Business briefs: GlaxoSmithKline and Spectrum

Share this article:

GlaxoSmithKline said the PDUFA goal date for albiglutide, its investigational once-weekly GLP-1 treatment for adult patients with type 2 diabetes, has been extended by three months to April 15, 2014, “to provide time for a full review of information submitted by GSK in response to the [FDA's] requests.” GSK filled a BLA to the FDA for albiglutide in January, followed by a submission to the EMA in March. GSK said the EMA filing is “progressing to schedule.” The drug would compete with BMS/AZ's Bydureon, also a once-weekly shot.

A professional sales aid from Spectrum Pharmaceuticals' cancer infusion Zevalin minimized risk information, overstates efficacy and omits material facts, said OPDP in an untitled letter dated July 23 and recently posted on the FDA website. OPDP said the conduct occurred despite repeated advisory comments addressing similar misleading presentations on five other occasions.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.